mPower Technology, Inc

Located in Albuquerque, N.M., RMCI provides general contracting services throughout the Southwest. The company serves public and private sector owners. It specializes in the construction of water and wastewater treatment plants, large-scale industrial projects, storm and sanitary sewers, water systems and large diameter utilities. The company has worked on various projects, including high-pressure pipes, drainage systems, pumping facilities, concrete reservoirs, flood diversion control structures and high-technology installations. Its projects include Cogeneration Facility Upgrade and Expansion, Ford Utilities Center Renovation and Rio Grande Silvery Minnow Rearing and Breeding Facility. RMCI was founded in 1990.

SolExergy LLC is a solar and wind construction contractor based in Rio Rancho, New Mexico, serving commercial and industrial clients since 2009. The company is licensed, bonded, and insured, specializing in a range of services including civil, mechanical, and electrical work, as well as site reclamation and hydroseeding. With a strong commitment to honesty, reliability, and quality, SolExergy prioritizes safety with a .91 Worker's Compensation Modifier. The company is a member of the Renewable Energy Industries Association and has garnered positive testimonials for its technical expertise and dedication to completing projects on time and within budget. Generated from the website

Agilvax, located in Albuquerque, NM, is a cutting-edge biotechnology company specializing in the development of cancer immunotherapies and targeted vaccines for infectious diseases. Their innovative approaches, such as checkpoint inhibitors and CAR T-cell therapy, aim to empower the patient's immune system to fight cancer cells and boost immune responses against infectious diseases. With a focus on personalized medicine, Agilvax is at the forefront of advancing treatment paradigms and bringing new hope to patients worldwide. Agilvax's groundbreaking research and development in precision medicine have led to remarkable success in treating various cancers, including melanoma and non-small cell lung cancer, with drugs like pembrolizumab and nivolumab. Additionally, their targeted vaccines, exemplified by the mRNA vaccines for COVID-19, demonstrate their commitment to disease prevention and the advancement of effective and accessible treatments. As they continue to push the boundaries of medical research and technology, Agilvax is poised to redefine the approach to some of the most challenging diseases of our time, offering new hope to patients everywhere.Generated from the website